Connect your AI

Xtant Medical Holdings XTNT PP&E Sale Proceeds

PP&E Sale Proceeds at other companies

Envista Holdings CorporationNVST

$100K-80.0%

Other financials

Income statement

Revenue$20.9M-36.5%

Gross profit$12.0M-40.9%

Operating income-$2.9M-375%

Net income-$3.1M-5,426%

EPS (diluted)-$0.02—

Balance sheet

Cash & equivalents$12.2M+124%

Total debt$15.0M-34.9%

Total equity$48.6M+10.8%

Total assets$78.0M-18.6%

Cash flow

Operating cash flow-$2.1M-265%

CapEx$194.0K-83.7%

Free cash flow-$2.3M-2,753%

Valuation

Market cap$59.05M-32.5%

Enterprise value$61.89M-41.5%

P/E32.3×—

P/S0.5×-0.2×

Profitability

Gross margin62.3%+4.2pp

Operating margin4.8%+2.8pp

Net margin1.5%+0.8pp

FCF margin6.4%+4.1pp

Returns & leverage

Return on equity3.9%+2.1pp

Debt / equity0.3×-0.2×

Current ratio3.3×+1.0×

Where this comes from

Reported directly by Xtant Medical Holdings in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment.

The official record: Xtant Medical Holdings’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xtant Medical Holdings's pp&e sale proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Xtant Medical Holdings's PP&E sale proceeds?: Xtant Medical Holdings (XTNT) reported PP&E sale proceeds of $46K in Q1 2026.
How has Xtant Medical Holdings's PP&E sale proceeds changed year-over-year?: Xtant Medical Holdings's PP&E sale proceeds decreased by 4.2% year-over-year, from $48K to $46K.
What is the long-term trend for Xtant Medical Holdings's PP&E sale proceeds?: Over 4 years (2021 to 2025), Xtant Medical Holdings's PP&E sale proceeds has grown at a 0.8% compound annual growth rate (CAGR), from $225K to $232K.
What does PP&E sale proceeds mean?: Cash received from selling property, plant, and equipment no longer needed for operations.